SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-193717
Filing Date
2023-07-26
Accepted
2023-07-25 18:58:59
Documents
13
Period of Report
2023-07-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d502173d8k.htm   iXBRL 8-K 26671
2 EX-10.1 d502173dex101.htm EX-10.1 134057
  Complete submission text file 0001193125-23-193717.txt   325186

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vtyx-20230721.xsd EX-101.SCH 2844
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vtyx-20230721_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vtyx-20230721_pre.xml EX-101.PRE 11703
7 EXTRACTED XBRL INSTANCE DOCUMENT d502173d8k_htm.xml XML 3472
Mailing Address 662 ENCINITAS BLVD., STE. 250 ENCINITAS CA 92024
Business Address 662 ENCINITAS BLVD., STE. 250 ENCINITAS CA 92024 (858) 945-2393
Ventyx Biosciences, Inc. (Filer) CIK: 0001851194 (see all company filings)

IRS No.: 832996852 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40928 | Film No.: 231109746
SIC: 2834 Pharmaceutical Preparations